<DOC>
	<DOC>NCT00758004</DOC>
	<brief_summary>To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.</brief_summary>
	<brief_title>Bioequivalence Study Of Pediatric Appropriate Formulation</brief_title>
	<detailed_description>Determination of Bioequivalence</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Healthy male and/or female volunteers Mass Index (BMI) of approximately 18 to 30 kg/m2 Any condition possibly affecting drug absorption A positive urine drug screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>